Jasper Therapeutics Receives Nasdaq Delisting Notice for Sub-$1.00 Bid Price
JSPR is trading near its 52-week low of $0.42 (11% above the low).
Summary
Jasper Therapeutics received a notice from Nasdaq regarding its failure to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period to avoid delisting.
Key Events · Corporate Governance and Compliance · JSPR
-
Nasdaq Delisting Notice Received
Jasper Therapeutics received a notice from Nasdaq on June 3, 2026, indicating its common stock failed to meet the minimum $1.00 bid price requirement for 30 consecutive business days.
-
180-Day Compliance Period
The company has an initial period of 180 calendar days, until November 30, 2026, to regain compliance by having its stock close at $1.00 or more for a minimum of ten consecutive business days.
-
No Immediate Effect on Listing
The notice does not immediately affect the listing or trading of the company's common stock or public warrants on the Nasdaq Capital Market.
-
Potential Reverse Stock Split
The company intends to monitor its stock price and may consider options, including a reverse stock split, if it does not regain compliance.
Analysis · JSPR · Life Sciences
This Nasdaq delisting notice significantly compounds Jasper Therapeutics' existing financial distress, which includes a 'going concern' warning and rapid cash burn as highlighted in recent filings. Failure to regain compliance by November 30, 2026, could lead to delisting, severely limiting the company's access to capital and investor interest. This is particularly critical given the ongoing strategic review, as delisting would complicate any potential sale or merger and further erode shareholder value. While a reverse stock split is an option, it often signals desperation and can be negatively perceived by investors.
At the time of this filing, JSPR was trading at $0.47 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $0.42 to $7.19. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.